14
Participants
Start Date
December 1, 2023
Primary Completion Date
December 1, 2028
Study Completion Date
December 31, 2029
JOINTSTEM
JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Lead Sponsor
R-Bio
INDUSTRY